BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Carino, Adriana ^a   Cipriani, Sabrina ^a   Marchianò, Silvia ^a   Biagioli, Michele ^a   Santorelli, Chiara ^a   Donini, Annibale ^a   Zampella, Angela ^b   Monti, Maria Chiara ^c   Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBON TETRACHLORIDE; CELL RECEPTOR; CHOLANE DERIVATIVE; FARNESOID X-ACTIVATED RECEPTOR; FRUCTOSE; G PROTEIN COUPLED RECEPTOR; GPBAR1 PROTEIN, HUMAN;

3T3-L1 CELL LINE; AGONISTS; ANIMAL; BROWN ADIPOSE TISSUE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECT; LIPID DIET; MALE; METABOLISM; MOUSE; NONALCOHOLIC FATTY LIVER; WHITE ADIPOSE TISSUE;

3T3-L1 CELLS; ADIPOSE TISSUE, BROWN; ADIPOSE TISSUE, WHITE; ANIMALS; BIOMARKERS; CARBON TETRACHLORIDE; CHOLANES; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FRUCTOSE; MALE; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85012934609     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep42801     Document Type: Article

References (51)

1. Sherif, Z. A. et al. Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Dig Dis Sci. 6, 1214-25 (2016).
2. Fiorucci, S. & Distrutti, E. Bile Acid-Activated Receptors, Intestinal Microbiota and the Treatment of Metabolic Disorders. Trends Mol Med 21, 702-14 (2015).
3. Mintziori, G. & Polyzos, S.-A. Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opin Pharmacother 26, 1-10 (2016).
4. Rosselli, M. et al. The metabolic syndrome and chronic liver disease. Curr Pharm Des 20, 5010-24 (2014).
5. Baffy, G., Brunt, E.-M. & Caldwell, S.-H. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J. Hepatol 56, 1384-1391 (2012).
6. Rubio, A. et al. Identification of a gene-pathway associated with non-alcoholic steatohepatitis. J Hepatol 46, 708-718 (2007).
7. Ekstedt, M. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61, 1547-1554 (2015).
8. Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389-397 (2015).
9. Farrell, G.-C., van Rooyen, D., Gan, L. & Chitturi, S. NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver 6, 149-171 (2012).
10. Buzzetti, E., Pinzani, M. & Tsochatzis, E.-A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism Clinical and Experimental 65, 1038-1048 (2016).
11. Takahashi, Y., Soejima, Y. & Fukusato, T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 18, 2300-8 (2012).
12. Teufel, A. et al. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Diseaseand Liver Tissues From Patients. Gastroenterology 151, 513-525 (2016).
13. Kohli, R. et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52, 934-944 (2010).
14. Fiorucci, S., Cipriani, S., Baldelli, F. & Mencarelli, A. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res 49, 171-85 (2010).
15. Fiorucci, S., Mencarelli, A., Palladino, G. & Cipriani, S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.Trends Pharmacol Sci 30, 570-80 (2009).
16. Mencarelli, A., Renga, B., Distrutti, E. & Fiorucci, S. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol 296, H272-81 (2009).
17. Cipriani, S., Mencarelli, A., Palladino, G. & Fiorucci, S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 51, 771-84 (2010).
18. Neuschwander-Tetri, B.-A. et al. NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956-65 (2015).
19. Nanthakumar, C. B. et al. Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nature Reviews Drug Discovery 14, 693-720 (2015)
20. Festa, C. et al. Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands. J Med Chem 57, 8477-95 (2014).
21. Fiorucci, S. et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127, 1497-512 (2004).
22. Kleiner, D.-E. et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-21 (2005).
23. Rizzo, G. et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol 70, 1164-73 (2006).
24. John, C. et al. A liquid chromatography-tandem mass spectrometry-based method for the simultaneous determination of hydroxy sterols and bile acids. J Chromatogr A. 1371, 184-95 (2014).
25. Keitel, V. & Haussinger, D. Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin Res Hepatol Gastroenterol. 36, 412-9 (2012).
26. Alemi, F. et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 144, 145-54 (2013).
27. Katsuma, S., Hirasawa, A. & Tsujimoto, G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329, 386-90 (2005).
28. Goodwin, B. et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 6, 517-26 (2000).
29. Watanabe, M. et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439, 484-9 (2006).
30. Renga, B. et al. Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. FASEB J. 26, 3021-31 (2012).
31. Lieu, T. et al. The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice. Gastroenterology 147, 1417-28 (2014).
32. Jakulj, L. et al. ABCG5/G8 polymorphisms and markers of cholesterol metabolism: systematic review and meta-analysis. J Lipid Res 51, 3016-23 (2010).
33. Silverstein, R.-L. & Febbraio, M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2, re3. doi: 10.1126/scisignal.272re3 (2009).
34. Miquilena-Colina, M.-E. et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut 60, 1394-402 (2011).
35. Song, K.-H., Li, T., Owsley, E., Strom, S. & Chiang, J.-Y. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 49, 297-305 (2009).
36. Townsend, K.-L. & Tseng, Y.-H. Brown adipose tissue: recent insights into development, metabolic function and therapeutic potential. Adipocyte 1, 13-24 (2012).
37. Frontini, A. & Cinti, S. Distribution and development of brown adipocytes in the murine and human adipose organ. Cell Metab 11, 253-6 (2010).
38. Wu, J. et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 150, 366-376 (2012).
39. Erlanson-Albertsson, C. The role of uncoupling proteins in the regulation of metabolism. Acta Physiol Scand 178, 405-12 (2003).
40. Seale, P. et al. Transcriptional control of brown fat determination by PRDM16. Cell Metab 6, 38-54 (2007).
41. Petrovic, N. et al. Chronic peroxisome proliferator-activated receptor ? (PPAR?) activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes. J Biol Chem 285, 7153-7164 (2010).
42. Almind, K., Manieri, M., Sivitz, W. I., Cinti, S. & Kahn, C. R. Ectopic brown adipose tissue in muscle provides a mechanism for differences in risk of metabolic syndrome in mice. Proc Natl Acad Sci USA 104, 2366-71(2007).
43. de Queiroz, K.-B. et al. Endurance training blocks uncoupling protein 1 up-regulation in brown adipose tissue while increasing uncoupling protein 3 in the muscle tissue of rats fed with a high-sugar diet. Nutr Res 32, 709-17 (2012).
44. Uldry, M. et al. Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metab 3, 333-341 (2006).
45. Cypess, A.-M. et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360, 1509-1517 (2009).
46. Virtanen, K.-A. et al. Functional brown adipose tissue in healthy adults. N Engl J Med 360, 1518-1525 (2009).
47. Whittle, A.-J., Lpez, M. & Vidal-Puig, A. Using brown adipose tissue to treat obesity-the central issue. Trends Mol Med 17, 405-411 (2011).
48. Fink, B.-D. et al. UCP2-dependent proton leak in isolated mammalian mitochondria. J Biol Chem 277, 3918-25 (2002).
49. Asano, H. et al. Induction of beige-like adipocytes in 3T3-L1 cells. J Vet Med Sci 76, 57-64 (2014).
50. Fiorucci, S. & Distrutti, E. Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension. Pharmacol Res. 111, 749-756 (2016).
51. Renga, B. et al. Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1. PLoS One 10, e0141082 (2015).